Prasad Ankshita, Manivannan Janani, Loong Daniel T B, Chua Soo M, Gharibani Payam M, All Angelo H
Departments of Orthopaedic Surgery, Biomedical Engineering & Medicine, Division of Neurology, Singapore Institute of Neurotechnology, National University of Singapore, Singapore.
Orthopaedic Surgery, Medicine, Division of Neurology, National University of Singapore, Singapore.
Regen Med. 2016 Mar;11(2):181-91. doi: 10.2217/rme.16.5. Epub 2016 Feb 9.
Rapid progress in the field of stem cell therapy and cellular reprogramming provides convincing evidence of its feasibility in treating a wide range of pathologies through autologous cell replacement therapy. This review article describes in detail on three widely used approaches of somatic cell reprogramming: induced pluripotent stem cells, direct conversion and direct reprogramming, in the context of demyelination in the CNS. The potential limitations of each reprogramming technique are reviewed along with their distinct molecular approach to reprogramming. This is followed by an analysis on the scopes and challenges of its translational applications in deriving oligodendrocyte progenitor cells and oligodendrocytes for cell replacement treatment of demyelinating conditions in the CNS.
干细胞治疗和细胞重编程领域的快速进展为通过自体细胞替代疗法治疗多种病症的可行性提供了令人信服的证据。这篇综述文章详细描述了在中枢神经系统脱髓鞘背景下,体细胞重编程的三种广泛使用的方法:诱导多能干细胞、直接转化和直接重编程。每种重编程技术的潜在局限性以及它们独特的重编程分子方法都进行了综述。随后分析了其在获得少突胶质细胞祖细胞和少突胶质细胞以用于中枢神经系统脱髓鞘疾病的细胞替代治疗的转化应用的范围和挑战。